Skip to main content
SpringerLink
Log in

Biomarkers for Anti-angiogenic Therapy

  • Reference work entry
  • First Online:
Tumor Angiogenesis

  • 547 Accesses

Abstract

The introduction of anti-angiogenic therapy has changed the clinical practice in a number of human malignancies. Despite this success, anti-angiogenic therapy frequently has only transient effects, with acquired drug resistance and tumor progression quickly to follow. The heterogeneous response to anti-angiogenic therapy has created a need for predictive biomarkers. This chapter reviews potential biomarkers for anti-angiogenic therapy focusing on tissue-based, blood-based, genetic, and epigenetic markers and lastly drug-related toxicity and imaging to determine therapeutic efficacy. Most studies summarized here were performed retrospectively in relatively small patient cohorts. Further confirmation in prospective and randomized clinical trials to establish superiority of one or a combination of biomarkers remains hence an ongoing task.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 439.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491. https://doi.org/10.1158/2159-8290.CD-15-1483.

    Article  CAS  PubMed  Google Scholar 

  • Almendro V, Marusyk A, Polyak K (2013) Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 8:277–302. https://doi.org/10.1146/annurev-pathol-020712-163923.

    Article  CAS  PubMed  Google Scholar 

  • Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L (2004) Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 10(18 Pt 2):6277S–6281S. https://doi.org/10.1158/1078-0432.CCR-040720.

    Article  PubMed  Google Scholar 

  • Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC (2014) The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 20(17):4549–4558. https://doi.org/10.1158/1078-0432.CCR-13-3248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME (2012) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 30(4):1773–1781. https://doi.org/10.1007/s10637-011-9652-2.

    Article  CAS  Google Scholar 

  • Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297

    Article  CAS  PubMed  Google Scholar 

  • Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ (2012) Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res: Off J Am Assoc Cancer Res 18(22):6384–6391. https://doi.org/10.1158/1078-0432.CCR-12-2223.

    Article  CAS  Google Scholar 

  • Belgiovine C, D’Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci: CMLS. https://doi.org/10.1007/s00018-016-2166-5.

    Article  PubMed  Google Scholar 

  • Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schoffski P, Mejean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinie V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S (2014) VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncol 53(1):103–112. https://doi.org/10.3109/0284186X.2013.770600.

    Article  PubMed  Google Scholar 

  • Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 21(9):1765–1771. https://doi.org/10.1093/annonc/mdq052.

    Article  Google Scholar 

  • Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM (2013) Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res: Off J Am Assoc Cancer Res 19(24):6967–6975. https://doi.org/10.1158/1078-0432.CCR-12-1818.

    Article  CAS  Google Scholar 

  • Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F (2012) Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 17(8):1063–1072. https://doi.org/10.1634/theoncologist.2011-0465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Borges NM, do Vale Elias M, Fook-Alves VL, Andrade TA, de Conti ML, Macedo MP, Begnami MD, Campos AH, Etto LY, Bortoluzzo AB, Alves AC, Young KH, Colleoni GW (2016) Angiomirs expression profiling in diffuse large B-Cell lymphoma. Oncotarget 7(4):4806–4816. https://doi.org/10.18632/oncotarget.6624.

    Article  PubMed  Google Scholar 

  • Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P (2013) Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 14(6):469–475. https://doi.org/10.4161/cbt.24425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–307. https://doi.org/10.1038/nature10144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL (2016a) eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. https://doi.org/10.18632/oncotarget.8569.

    Article  PubMed  Google Scholar 

  • Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL (2016b) Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget. https://doi.org/10.18632/oncotarget.7444.

    Article  PubMed  Google Scholar 

  • Chan JK, Kiet TK, Blansit K, Ramasubbaiah R, Hilton JF, Kapp DS, Matei D (2014) MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol 133(3):568–574. https://doi.org/10.1016/j.ygyno.2014.03.564.

    Article  CAS  PubMed  Google Scholar 

  • Choi SH, Jung SC, Kim KW, Lee JY, Choi Y, Park SH, Kim HS (2016) Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neuro-Oncol 128(2):185–194. https://doi.org/10.1007/s11060-016-2102-4.

    Article  CAS  Google Scholar 

  • Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180(3):860–865; discussion 865–866. https://doi.org/10.1016/j.juro.2008.05.015.

  • Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S (2013) The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 19(18):5218–5226. https://doi.org/10.1158/1078-0432.CCR-13-0491.

    Article  CAS  Google Scholar 

  • Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704–714. https://doi.org/10.1038/nrg2634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • D’Alessandris QG, Martini M, Cenci T, Capo G, Ricci-Vitiani L, Larocca LM, Pallini R (2015) VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. Neurology 84(18):1906–1908. https://doi.org/10.1212/WNL.0000000000001543.

    Article  PubMed  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954. https://doi.org/10.1038/nature00766.

    Article  CAS  PubMed  Google Scholar 

  • Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, Scartozzi M, Cascinu S (2015) Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 6(32):33982–33992. https://doi.org/10.18632/oncotarget.5053.

    Article  PubMed  PubMed Central  Google Scholar 

  • Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, Bougnaud S, Bjerkvig R, Domon B, Niclou SP (2016) Targeted proteomics to assess the response to anti-angiogenic treatment in human glioblastoma (GBM). Mol Cell Proteomics: MCP 15(2):481–492. https://doi.org/10.1074/mcp.M115.052423.

    Article  CAS  PubMed  Google Scholar 

  • Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodriguez-Antona C, Garcia-Donas J, Rini BI, Guchelaar HJ (2015) CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol 68(4):621–629. https://doi.org/10.1016/j.eururo.2015.04.018.

    Article  CAS  PubMed  Google Scholar 

  • Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, Payzin KB, Bayoglu IV, Akyol M, Yildiz Y, Koeseoglu M, Alacacioglu A, Tarhan MO (2013) Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev 14(3):2101–2105

    Article  PubMed  Google Scholar 

  • Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, Wirth MP, Zastrow S, Fuessel S (2013) Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 8(9):e76386. https://doi.org/10.1371/journal.pone.0076386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dorner AJ, Badola S, Niu H (2015) Characterization of circulating tumor DNA for genetic assessment of solid tumors. Clin Pharmacol Ther 98(1):16–18. https://doi.org/10.1002/cpt.130.

    Article  CAS  PubMed  Google Scholar 

  • Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11–22. https://doi.org/10.1038/nrc969.

    Article  CAS  PubMed  Google Scholar 

  • Dubrowinskaja N, Gebauer K, Peters I, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Grunwald V, Kuczyk MA, Serth J (2014) Neurofilament heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med 3(2):300–309. https://doi.org/10.1002/cam4.181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK (2010) Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15(6):577–583. https://doi.org/10.1634/theoncologist.2010-0029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duffaud F, Sleijfer S, Litiere S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schoffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT (2015) Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Eur J Cancer 51(17):2615–2623. https://doi.org/10.1016/j.ejca.2015.08.002.

    Article  CAS  PubMed  Google Scholar 

  • Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, Savas S, Mackay HJ, Amir E, Liu G (2012) Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res: Off J Am Assoc Cancer Res 18(17):4526–4537. https://doi.org/10.1158/1078-0432.CCR-12-1315.

    Article  CAS  Google Scholar 

  • Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Bottcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ (2016) Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76(3):525–534. https://doi.org/10.1158/0008-5472.CAN-15-0776.

    Article  CAS  PubMed  Google Scholar 

  • Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z, Hu X (2014) Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 143(1):141–151. https://doi.org/10.1007/s10549-013-2793-6.

    Article  CAS  PubMed  Google Scholar 

  • Fan Y, Li H, Ma X, Gao Y, Chen L, Li X, Bao X, Du Q, Zhang Y, Zhang X (2015) Prognostic significance of hypoxia-inducible factor expression in renal cell carcinoma: a PRISMA-compliant systematic review and meta-analysis. Medicine 94(38):e1646. https://doi.org/10.1097/MD.0000000000001646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527. https://doi.org/10.1038/nm1764.

    Article  CAS  PubMed  Google Scholar 

  • Fleitas T, Martinez-Sales V, Gomez-Codina J, Martin M, Reynes G (2010) Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clin Transl Oncol: Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 12(8):521–525. https://doi.org/10.1007/s12094-010-0549-x.

    Article  CAS  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. https://doi.org/10.1056/NEJM197111182852108.

    Article  CAS  PubMed  Google Scholar 

  • Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM (2011) Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic cooperative oncology group experience with biological marker evaluation. Anticancer Res 31(9):3007–3018

    CAS  PubMed  Google Scholar 

  • Gamez-Pozo A, Anton-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, Garcia-Dominguez R, de Portugal T, Ramos-Vazquez M, Perez-Carrion R, Bolos MV, Madero R, Sanchez-Navarro I, Fresno Vara JA, Espinosa Arranz E (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14(12):1144–1152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garcia-Donas J, Leandro-Garcia LJ, Gonzalez Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodriguez-Antona C (2013) Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(9):2409–2414. https://doi.org/10.1093/annonc/mdt219.

    Article  CAS  Google Scholar 

  • Gerger A, LaBonte M, Lenz HJ (2011) Molecular predictors of response to antiangiogenesis therapies. Cancer J 17(2):134–141. https://doi.org/10.1097/PPO.0b013e318212db3c.

    Article  CAS  PubMed  Google Scholar 

  • Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M (2011) Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res: BCR 13(3):R67. https://doi.org/10.1186/bcr2907.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gossage L, Eisen T (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7(5):277–288. https://doi.org/10.1038/nrclinonc.2010.42.

    Article  CAS  PubMed  Google Scholar 

  • Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, Haubitz M (2010) Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 10:695. https://doi.org/10.1186/1471-2407-10-695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hansen TF, Carlsen AL, Heegaard NH, Sorensen FB, Jakobsen A (2015) Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer 112(4):624–629. https://doi.org/10.1038/bjc.2014.652.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res: Off J Am Assoc Cancer Res 19(4):929–937. https://doi.org/10.1158/1078-0432.CCR-12-2535.

    Article  CAS  Google Scholar 

  • Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13(10):679–692. https://doi.org/10.1038/nrg3270.

    Article  CAS  PubMed  Google Scholar 

  • Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ (2009) Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 9:246. https://doi.org/10.1186/1471-2407-9-246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hudson JM, Williams R, Tremblay-Darveau C, Sheeran PS, Milot L, Bjarnason GA, Burns PN (2015) Dynamic contrast enhanced ultrasound for therapy monitoring. Eur J Radiol 84(9):1650–1657. https://doi.org/10.1016/j.ejrad.2015.05.013.

    Article  PubMed  Google Scholar 

  • Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H (2006) Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(2):217–227. https://doi.org/10.1200/JCO.2005.01.5388.

    Article  CAS  Google Scholar 

  • Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H (2011) Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 17(2):372–381. https://doi.org/10.1158/1078-0432.CCR-10-1791.

    Article  CAS  Google Scholar 

  • Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV (2015) CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. AJR Am J Roentgenol 204(1):W11–W18. https://doi.org/10.2214/AJR.13.12412.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G (2012) Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev 13(12):6397–6401

    Article  PubMed  Google Scholar 

  • Khella HW, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM (2015) miR-221/222 are involved in response to sunitinib treatment in metastatic renal cell carcinoma. Mol Ther: J Am Soc Gene Ther 23(11):1748–1758. https://doi.org/10.1038/mt.2015.129.

    Article  CAS  Google Scholar 

  • Kim J, Hwang J, Jeong H, Song HJ, Shin J, Hur G, Park YW, Lee SH, Kim J (2012) Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics 7(2):191–200. https://doi.org/10.4161/epi.7.2.18973.

    Article  CAS  PubMed  Google Scholar 

  • Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33(6):679–689. https://doi.org/10.1038/onc.2012.636.

    Article  CAS  PubMed  Google Scholar 

  • Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol Off J Am Soc Clin Oncol 28(3):453–459. https://doi.org/10.1200/JCO.2009.24.8252.

    Article  CAS  Google Scholar 

  • Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11(3):129–144. https://doi.org/10.1038/nrclinonc.2013.253.

    Article  CAS  PubMed  Google Scholar 

  • Labussiere M, Cheneau C, Prahst C, Gallego Perez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A, Sanson M (2016) Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma. Cancer Investig 34(1):39–44. https://doi.org/10.3109/07357907.2015.1088948.

    Article  CAS  Google Scholar 

  • Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E, team ATXt (2016) Angiogenesis- and hypoxia-associated proteins as early indicators of the outcome in patients with metastatic breast cancer given first-line bevacizumab-based therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 22(7):1611–1620. https://doi.org/10.1158/1078-0432.CCR-15-1005.

    Article  CAS  Google Scholar 

  • Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol Off J Am Soc Clin Oncol 31(9):1219–1230. https://doi.org/10.1200/JCO.2012.46.2762.

    Article  CAS  Google Scholar 

  • Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S (2014) Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Investig Radiol 49(12):794–800. https://doi.org/10.1097/RLI.0000000000000085.

    Article  CAS  Google Scholar 

  • Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM (2013) Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol 2(1):33–47. https://doi.org/10.2217/cns.12.29.

    Article  CAS  PubMed  Google Scholar 

  • Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M (2016) Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2(1):49–63. https://doi.org/10.1016/j.trecan.2015.11.003.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lokmic Z, Mitchell GM (2011) Visualisation and stereological assessment of blood and lymphatic vessels. Histol Histopathol 26(6):781–796

    PubMed  Google Scholar 

  • Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK (2013) Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology 15(8):1079–1087. https://doi.org/10.1093/neuonc/not082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Manzoni M, Comolli G, Torchio M, Mazzini G, Danova M (2015) Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer. Clin Colorectal Cancer 14(1):11–17. https://doi.org/10.1016/j.clcc.2014.12.002.

    Article  PubMed  Google Scholar 

  • Massey PR, Okman JS, Wilkerson J, Cowen EW (2015) Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 23(6):1827–1835. https://doi.org/10.1007/s00520-014-2520-9.

    Article  Google Scholar 

  • Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K (2011) Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer 117(17):4026–4032. https://doi.org/10.1002/cncr.25977.

    Article  CAS  PubMed  Google Scholar 

  • McLeod HL, Yu J (2003) Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Investig 21(4):630–640

    Article  CAS  Google Scholar 

  • Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T (2013) Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol 43(10):1023–1029. https://doi.org/10.1093/jjco/hyt110.

    Article  PubMed  Google Scholar 

  • Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L (2014) Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer 110(1):26–33. https://doi.org/10.1038/bjc.2013.719.

    Article  CAS  PubMed  Google Scholar 

  • Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV (2010) Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70(6):2171–2179. https://doi.org/10.1158/0008-5472.CAN-09-2533.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, Alliance for Clinical Trials In O (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (alliance). Clin Cancer Res: Off J Am Assoc Cancer Res 19(24):6957–6966. https://doi.org/10.1158/1078-0432.CCR-13-0926.

    Article  CAS  Google Scholar 

  • Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG (2015) 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med: Off Publ Soc Nucl Med 56(1):63–69. https://doi.org/10.2967/jnumed.114.144840.

    Article  CAS  Google Scholar 

  • Pagliarini R, Shao W, Sellers WR (2015) Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports 16(3):280–296. https://doi.org/10.15252/embr.201439949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T (2014) Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. https://doi.org/10.1097/COC.0000000000000108.

    Article  Google Scholar 

  • Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C (2014) Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol 9(3):273–277. https://doi.org/10.1007/s11523-013-0299-0.

    Article  PubMed  Google Scholar 

  • Peters I, Dubrowinskaja N, Abbas M, Seidel C, Kogosov M, Scherer R, Gebauer K, Merseburger AS, Kuczyk MA, Grunwald V, Serth J (2014) DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS One 9(3):e91440. https://doi.org/10.1371/journal.pone.0091440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S (2013) KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol 30(3):650. https://doi.org/10.1007/s12032-013-0650-4.

    Article  CAS  PubMed  Google Scholar 

  • Pomme G, Augustin F, Fiegl M, Droeser RA, Sterlacci W, Tzankov A (2015) Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Arch: Int J Pathol 467(1):55–66. https://doi.org/10.1007/s00428-015-1767-y.

    Article  CAS  Google Scholar 

  • Ramcharan KS, Lip GY, Stonelake PS, Blann AD (2015) Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. Int J Color Dis 30(3):315–321. https://doi.org/10.1007/s00384-014-2116-3.

    Article  CAS  Google Scholar 

  • Riethdorf S, Pantel K (2008) Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiol: J Immunopathol Mol Cell Biol 75(2):140–148. https://doi.org/10.1159/000123852.

    Article  Google Scholar 

  • Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98(4):756–762. https://doi.org/10.1111/j.1464-410X.2006.06376.x.

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763–773. https://doi.org/10.1093/jnci/djr128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD (2010a) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56(6):1131–1136. https://doi.org/10.1161/HYPERTENSIONAHA.110.160481.

    Article  CAS  PubMed  Google Scholar 

  • Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010b) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30(6):591–601. https://doi.org/10.1016/j.semnephrol.2010.09.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R (2012) Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer 107(8):1286–1294. https://doi.org/10.1038/bjc.2012.388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y (2015) Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget 6(25):21636–21644. https://doi.org/10.18632/oncotarget.4270.

    Article  PubMed  PubMed Central  Google Scholar 

  • Santos LV, Cruz MR, Lopes Gde L, Lima JP (2015) VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 151(3):481–489. https://doi.org/10.1007/s10549-015-3410-7.

    Article  CAS  PubMed  Google Scholar 

  • Sastre J, Vidaurreta M, Gomez A, Rivera F, Massuti B, Lopez MR, Abad A, Gallen M, Benavides M, Aranda E, Rubio ED, Spanish Cooperative Group for the Treatment of Digestive T (2013) Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer 12(4):280–286. https://doi.org/10.1016/j.clcc.2013.06.001.

    Article  CAS  PubMed  Google Scholar 

  • Schneider BP, Shen F, Miller KD (2012) Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 13(10):e427–e436. https://doi.org/10.1016/S1470-2045(12)70275-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shah DR, Shah RR, Morganroth J (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 36(6):413–426. https://doi.org/10.1007/s40264-013-0050-x.

    Article  CAS  PubMed  Google Scholar 

  • Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J (2014) Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One 9(6):e98259. https://doi.org/10.1371/journal.pone.0098259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sleijfer S, Gorlia T, Lamers C, Burger H, Blay JY, Le Cesne A, Scurr M, Collin F, Pandite L, Marreaud S, Hohenberger P (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer 107(4):639–645. https://doi.org/10.1038/bjc.2012.328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song Y, Huang J, Shan L, Zhang HT (2015) Analyses of potential predictive markers and response to targeted therapy in patients with advanced clear-cell renal cell carcinoma. Chin Med J 128(15):2026–2033. https://doi.org/10.4103/0366-6999.161353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stewart GD, O’Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock AL, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill SA, Riddick AC, Aitchison M, Berney D, Bex A, Overton IM, Harrison DJ, Powles T (2014) Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol 66(5):956–963. https://doi.org/10.1016/j.eururo.2014.04.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T (2016) Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.9187.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E (2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16(8):937–948. https://doi.org/10.1016/S1470-2045(15)00138-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A (2013) Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 30(1):327. https://doi.org/10.1007/s12032-012-0327-4.

    Article  CAS  PubMed  Google Scholar 

  • Tazzyman S, Niaz H, Murdoch C (2013) Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol 23(3):149–158. https://doi.org/10.1016/j.semcancer.2013.02.003.

    Article  CAS  PubMed  Google Scholar 

  • Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2016) Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharm J 16(1):47–53. https://doi.org/10.1038/tpj.2015.13.

    Article  CAS  Google Scholar 

  • Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK (2015) Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A 112(46):14325–14330. https://doi.org/10.1073/pnas.1518808112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827–837. https://doi.org/10.1016/S1470-2045(12)70241-3.

    Article  CAS  PubMed  Google Scholar 

  • Travnicek I, Branzovsky J, Kalusova K, Hes O, Holubec L, Pele KB, Urge T, Hora M (2015) Tissue biomarkers in predicting response to Sunitinib treatment of metastatic renal cell carcinoma. Anticancer Res 35(10):5661–5666

    CAS  PubMed  Google Scholar 

  • Turley SJ, Cremasco V, Astarita JL (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15(11):669–682. https://doi.org/10.1038/nri3902.

    Article  CAS  PubMed  Google Scholar 

  • Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D (2015) eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. J Transl Med 13:258. https://doi.org/10.1186/s12967-015-0619-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di Tommaso L, Fagiuoli S, Rota Caremoli E, Barberis M, Labianca R, Santoro A, Bosari S (2015) MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int: Off J Int Assoc Stud Liver 35(3):1077–1086. https://doi.org/10.1111/liv.12636.

    Article  CAS  Google Scholar 

  • Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 30(17):2119–2127. https://doi.org/10.1200/JCO.2011.39.9824.

    Article  CAS  Google Scholar 

  • Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, Speeckaert M (2012) DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 751(2):304–325. https://doi.org/10.1016/j.mrrev.2012.06.001.

    Article  CAS  Google Scholar 

  • Wang S, Olson EN (2009) AngiomiRs – key regulators of angiogenesis. Curr Opin Genet Dev 19(3):205–211. https://doi.org/10.1016/j.gde.2009.04.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilson MA, Zhao F, Letrero R, D’Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL (2014) Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib. Clin Cancer Res: Off J Am Assoc Cancer Res 20(12):3328–3337. https://doi.org/10.1158/1078-0432.CCR-14-0093.

    Article  CAS  Google Scholar 

  • Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, Weissleder R, Breakefield XO, Krichevsky AM (2008) miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14(5):382–393. https://doi.org/10.1016/j.ccr.2008.10.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM (2008) Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14(18):5893–5899. https://doi.org/10.1158/1078-0432.CCR-07-4762.

    Article  CAS  Google Scholar 

  • You D, Song SH, Cho YM, Lee JL, Jeong IG, Song C, Hong JH, Kim CS, Ahn H (2015) Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World J Urol 33(1):111–118. https://doi.org/10.1007/s00345-014-1295-4.

    Article  CAS  PubMed  Google Scholar 

  • Zebisch A, Troppmair J (2006) Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci: CMLS 63(11):1314–1330. https://doi.org/10.1007/s00018-006-6005-y.

    Article  CAS  PubMed  Google Scholar 

  • Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res: Off J Am Assoc Cancer Res 16(13):3420–3430. https://doi.org/10.1158/1078-0432.CCR-09-2904.

    Article  CAS  Google Scholar 

  • Zhang L, Zhou Q, Ma L, Wu Z, Wang Y (2011) Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 36(4):344–350. https://doi.org/10.1111/j.1365-2230.2011.04060.x.

    Article  CAS  PubMed  Google Scholar 

  • Zhao YY, Xue C, Jiang W, Zhao HY, Huang Y, Feenstra K, Resau JH, Qian CN, Zhang L (2012) Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. J Thorac Oncol: Off Publi Int Assoc Stud Lung Cancer 7(1):71–75. https://doi.org/10.1097/JTO.0b013e31823085f4.

    Article  Google Scholar 

  • Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, He X, Fu SR, Zhao Y, Li Y, Hu BS, Lu LG (2014) The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Med Oncol 31(10):209. https://doi.org/10.1007/s12032-014-0209-z.

    Article  CAS  PubMed  Google Scholar 

  • Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J (2016) Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology. https://doi.org/10.1053/j.gastro.2016.02.040.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 27(18):3027–3035. https://doi.org/10.1200/JCO.2008.20.9908.

    Article  CAS  Google Scholar 

  • Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV (2015) Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer 112(7):1199–1205. https://doi.org/10.1038/bjc.2015.73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Work in the authors’ laboratory is supported by the Medical Faculty Heidelberg. W.H. is supported by a fellowship from the China Scholarship Council (CSC).

Author information

Authors and Affiliations

  1. Department of Urology, Section of Molecular Urooncology, University of Heidelberg, Heidelberg, Germany

    Weibin Hou & Stefan Duensing

  2. School of Medicine, Medical Faculty Heidelberg, Heidelberg, Germany

    Weibin Hou & Stefan Duensing

Authors
  1. Weibin Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Duensing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Duensing .

Editor information

Editors and Affiliations

  1. Tumor Biology Center, Freiburg, Baden-Württemberg, Germany

    Dieter Marmé

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Hou, W., Duensing, S. (2019). Biomarkers for Anti-angiogenic Therapy. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-33673-2_32

Download citation

Publish with us

Policies and ethics

Search

Navigation